NASDAQ:CUTR - Cutera Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $13.58 -0.21 (-1.52 %) (As of 01/23/2019 04:00 PM ET)Previous Close$13.79Today's Range$13.52 - $13.9452-Week Range$12.32 - $56.05Volume88,202 shsAverage Volume327,660 shsMarket Capitalization$188.82 millionP/E Ratio17.64Dividend YieldN/ABeta1.03 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cutera, Inc., a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating. It also provides excel V, a vascular and benign pigmented lesion treatment platform; xeo platform, a multi-application platform on which a customer purchases hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin rejuvenation by treating discoloration, fine lines, and laxity; Juliet, a laser system for vaginal health; and Secret RF, a fractional radio frequency microneedling device for skin rejuvenation. In addition, the company offers GenesisPlus system, a laser product for use in the temporary increase of clear nails in patients with onychomycosis, as well as for the treatment of fine wrinkles, diffuse redness, and rosacea; and CoolGlide, as well as myQ, a third-party sourced system for the Japanese market. Further, it provides pulsed light hand pieces for the treatment of discoloration, hair removal, and vascular treatments; Pearl and Pearl Fractional hand pieces; and post-warranty services through extended service contracts or direct billing, as well as offers Titan hand piece refills and marketing brochures through the Internet. The company markets and sells its products through direct sales force to plastic surgeons, dermatologists, gynecologists, family practitioners, primary care physicians, physicians performing aesthetic treatments in non-medical offices, and other qualified practitioners, as well as for physicians offering aesthetic treatments in non-medical offices. Cutera, Inc. was founded in 1998 and is headquartered in Brisbane, California. Receive CUTR News and Ratings via Email Sign-up to receive the latest news and ratings for CUTR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorComputer and Technology Current SymbolNASDAQ:CUTR Previous Symbol CUSIPN/A Webwww.cutera.com Phone415-657-5500Debt Debt-to-Equity RatioN/A Current Ratio1.93 Quick Ratio1.24Price-To-Earnings Trailing P/E Ratio17.64 Forward P/E Ratio-46.83 P/E GrowthN/A Sales & Book Value Annual Sales$151.49 million Price / Sales1.25 Cash Flow$0.8430 per share Price / Cash Flow16.11 Book Value$4.68 per share Price / Book2.90Profitability EPS (Most Recent Fiscal Year)$0.77 Net Income$29.99 million Net Margins11.16% Return on Equity-0.50% Return on Assets-0.30%Miscellaneous Employees367 Outstanding Shares13,904,000Market Cap$188.82 million OptionableOptionable Cutera (NASDAQ:CUTR) Frequently Asked Questions What is Cutera's stock symbol? Cutera trades on the NASDAQ under the ticker symbol "CUTR." How will Cutera's stock buyback program work? Cutera announced that its Board of Directors has authorized a stock repurchase plan on Tuesday, August 8th 2017, which authorizes the company to repurchase $25,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's management believes its stock is undervalued. How were Cutera's earnings last quarter? Cutera, Inc. (NASDAQ:CUTR) issued its earnings results on Tuesday, November, 6th. The medical device company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.08. The medical device company earned $40.60 million during the quarter, compared to the consensus estimate of $40.03 million. Cutera had a net margin of 11.16% and a negative return on equity of 0.50%. The business's revenue was up 6.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.42 EPS. View Cutera's Earnings History. When is Cutera's next earnings date? Cutera is scheduled to release their next quarterly earnings announcement on Wednesday, February 13th 2019. View Earnings Estimates for Cutera. What guidance has Cutera issued on next quarter's earnings? Cutera issued an update on its FY18 earnings guidance on Tuesday, November, 6th. The company provided earnings per share guidance of $0.40-0.50 for the period, compared to the Thomson Reuters consensus estimate of $0.31. The company issued revenue guidance of $165-170 million, compared to the consensus revenue estimate of $166.27 million.Cutera also updated its FY 2018 guidance to $0.40-0.50 EPS. What price target have analysts set for CUTR? 5 brokerages have issued twelve-month price targets for Cutera's stock. Their forecasts range from $24.94 to $50.00. On average, they expect Cutera's share price to reach $34.6467 in the next twelve months. This suggests a possible upside of 155.1% from the stock's current price. View Analyst Price Targets for Cutera. What is the consensus analysts' recommendation for Cutera? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cutera in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cutera. What are Wall Street analysts saying about Cutera stock? Here are some recent quotes from research analysts about Cutera stock: 1. Maxim Group analysts commented, "Market open, CUTR reported lower-than-expected preliminary 4Q18 revenue. The company also announced the resignation of CEO James Reinstein amid Board dissatisfaction with 2018 operational results and stock price performance. CUTR plans to report full 4Q18 results on Market close." (1/8/2019) 2. According to Zacks Investment Research, "Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. " (1/4/2019) 3. Gabelli analysts commented, "As a leading laser dermatology company, Cutera is an attractive long-term investment as management focuses on execution, growing sales and improving operating performance. Throughout 2017, Cutera revamped several members of its management team, including its CEO and CFO, along with several new hires to build out its sales and operational infrastructure in the US and internationally. Management is putting in place new processes to improve upon product development and scale up its organization for sustainable growth." (2/16/2018) Has Cutera been receiving favorable news coverage? Media headlines about CUTR stock have trended very positive recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cutera earned a coverage optimism score of 3.7 on InfoTrie's scale. They also assigned news stories about the medical device company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. Who are some of Cutera's key competitors? Some companies that are related to Cutera include Viewray (VRAY), AxoGen (AXGN), Semler Scientific (SMLR), BioLife Solutions (BLFS), Rockwell Medical (RMTI), Electrocore (ECOR), Fonar (FONR), Zynex (ZYXI), Edap Tms (EDAP), Biosig Technologies (BSGM), Stereotaxis (STXS), IRIDEX (IRIX), Second Sight Medical Products (EYES), Viveve Medical (VIVE) and Soleno Therapeutics (SLNO). Who are Cutera's key executives? Cutera's management team includes the folowing people: Ms. Sandra A. Gardiner, Exec. VP & CFO (Age 53)Mr. Larry E. Laber, Exec. VP of Sales - North America (Age 48)Mr. Ronald J. Santilli, Exec. Officer (Age 59)Mr. Jason Richey, Interim CEO & Chief Operating OfficerDr. Michael Karavitis, Exec. VP & Chief Technology Officer Who are Cutera's major shareholders? Cutera's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Summit Creek Advisors LLC (0.94%), Assenagon Asset Management S.A. (0.53%) and Bank of Montreal Can (0.05%). Company insiders that own Cutera stock include David A Gollnick, David B Apfelberg, Gregory A Barrett, J Daniel Plants, James A Reinstein, Larry Laber, Miguel Pardos, Ronald J Santilli and Timothy J Oshea. View Institutional Ownership Trends for Cutera. Which institutional investors are selling Cutera stock? CUTR stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Summit Creek Advisors LLC. Company insiders that have sold Cutera company stock in the last year include David A Gollnick and Larry Laber. View Insider Buying and Selling for Cutera. Which institutional investors are buying Cutera stock? CUTR stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. Company insiders that have bought Cutera stock in the last two years include Gregory A Barrett and James A Reinstein. View Insider Buying and Selling for Cutera. How do I buy shares of Cutera? Shares of CUTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cutera's stock price today? One share of CUTR stock can currently be purchased for approximately $13.58. How big of a company is Cutera? Cutera has a market capitalization of $188.82 million and generates $151.49 million in revenue each year. The medical device company earns $29.99 million in net income (profit) each year or $0.77 on an earnings per share basis. Cutera employs 367 workers across the globe. What is Cutera's official website? The official website for Cutera is http://www.cutera.com. How can I contact Cutera? Cutera's mailing address is 3240 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The medical device company can be reached via phone at 415-657-5500 or via email at [email protected] MarketBeat Community Rating for Cutera (NASDAQ CUTR)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 232 (Vote Outperform)Underperform Votes: 213 (Vote Underperform)Total Votes: 445MarketBeat's community ratings are surveys of what our community members think about Cutera and other stocks. Vote "Outperform" if you believe CUTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUTR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/23/2019 by MarketBeat.com StaffFeatured Article: What is the quiet period?